Skip to main content

Table 3 Cost and clinical effects

From: Cost-effectiveness of polymyxin B hemoperfusion for septic shock: an observational study using a Japanese nationwide administrative database

 

PMX (n = 965)

Control (n = 2895)

Difference

P value

Hospital visit/management (SD)

142 (119)

126 (118)

16

0.0003

Prescription (SD)

250 (497)

247 (614)

3

0.8693

Injection (SD)

5677 (8175)

4827 (6552)

850

 < 0.0001

Treatment (SD)

7514 (4564)

3053 (4821)

4461

 < 0.0001

Surgery/anesthesia (SD)

4321 (7032)

3724 (8208)

597

0.0261

Laboratory test (SD)

1045 (1268)

1004 (1482)

40

0.3644

Diagnostic imaging (SD)

749 (579)

663 (625)

86

 < 0.0001

Rehabilitation (SD)

726 (873)

57 (819)

190

 < 0.0001

General hospitalization fee (SD)

4493 (3374)

4013 (3560)

480

 < 0.0001

ER/ICU hospitalization fee (SD)

6093 (4564)

5947 (4726)

146

0.3995

Meals (SD)

408 (357)

341 (362)

67

 < 0.0001

Total cost (SD)

31,418 (21,144)

24,483 (21,762)

6935

 < 0.0001

Life expectancy (years)

12.93

11.23

1.70

 

LYG (years)

6.59

5.73

0.86

 

QALY (years)

4.55

3.95

0.60

 

ICER (Euro/year)

  

11,592

 
  1. Costs are expressed as mean (SD) in Euro
  2. SD Standard deviation, LYG Life year gained, QALY Quality-adjusted life-year, ICER Incremental cost- effectiveness ratio